CureApp, Inc.: CureApp: Digital Hypertension Therapy App Reimbursed by Insurance Companies

Support lifestyle changes to treat high blood pressure

CureApp, Inc. (Headquarters: Chuo-ku, Tokyo; Kohta Satake) announces that the cost of CureApp HT adjuvant treatment application for hypertension (hereinafter CureApp HT), a DTx*1-Hypertension treatment solution to be reimbursed by insurance companies in Japan from September 1, 2022. In the future, the application will be prescribed and made available to patients with high blood pressure in medical centers as a service Health insurance.

This press release contains multimedia content. See the full announcement here: https://www.businesswire.com/news/home/20221031005331/en/

Helping Lifestyle Changes as a Treatment for Hypertension (Graphic: Business Wire)

Helping Lifestyle Changes as a Treatment for Hypertension (Graphic: Business Wire)

After confirming the efficacy and safety of CureApp HT in clinical studies, the results of a Japanese multicenter, randomized, controlled Phase III study were published in 2021 in EHJ, one of the world’s most respected scientific journals. In April 2022, CureApp HT received government approval as the world’s first digital therapy app for high blood pressure, and from September 1, insurance companies cover the costs of the app. This is the first case in the world where a DTx hypertension treatment solution is covered by health insurance. Going forward, CureApp aims to further commercialize this Japanese-led medical innovation. The effects of hypertension are felt beyond the borders of Japan, and efforts are underway around the world to correct patients’ lifestyles accordingly. With this in mind, CureApp plans to proactively expand CureApp HT’s reach around the world, starting with the United States.

Significance of lifestyle changes, current challenges and the potential of CureApp HT

The 2019 hypertension treatment guidelines state that “lifestyle changes are important because they not only have an antihypertensive effect, but also prevent hypertension.” The guidelines also state that “lifestyle counseling should be provided to all patients with hypertension, as lifestyle choices may increase the antihypertensive effect and decrease the dose of antihypertensive medications.” Despite this recommendation, such behavioral therapy has rarely been used due to the difficulty in persuading patients to make ongoing lifestyle changes and the limited time available for medical consultation. It also means that over a period of time, a guided intervention*two necessary for lifestyle changes to occur.

CureApp HT helps bring doctors and patients together and encourages lifestyle changes that were previously difficult to maintain. At the same time, the app ensures that patients change their behavior permanently.

*1 Short for “digital therapy.” Products with pharmaceutical approval for use as medical devices.

*two Kamioka H, ​​Nakamura Y, Yazaki T, Uebaba K, Mutoh Y, Okada S, Takahashi M. Comprehensive health education combining hot spring baths and lifestyle education in middle-aged and elderly women: follow-up of a year in randomized controlled trials trial of three and six month interventions. J Epidemic. 2006 January; 16(1):35-44. doi: 10.2188/jea.16.35. PMID: 16369107; PMID: PMC7560544.

Summary of clinical studies of this product

https://doi.org/10.1093/eurheartj/ehab559

About CureApp, Inc.

CureApp, Inc. is a MedTech company that conducts research and development to create medical device programs that apply advanced software technology and medical knowledge to the treatment of disease in order to manufacture and distribute medical devices. The company is working hard to develop “therapeutic applications”, that is, applications used to treat diseases, and aims to become the first company in Japan to establish a new health care service focused on “providing a therapeutic effect for the treatment of diseases”. using an app.” In August 2020, CureApp became the first company to receive regulatory approval as a medical device for a disease treatment app in Japan. This was a nicotine addiction treatment app that was reimbursed by the National Health Insurance Fund in December of the same year.

Projects in which CureApp participates:

nicotine addiction

Received medical device regulatory approval in August 2020; reimbursed by the national health insurance and prescriptions from December of the same year.

high blood pressure

It received regulatory approval for medical devices in April 2022.

NASH

(Non-Alcoholic Steatohepatitis)

Jointly developed with Sawai Group Holdings Co.

The app is currently in development and clinical testing with Tokyo University Hospital.

Alcohol addiction

The app is currently being developed in collaboration with the Kurihama Addiction and Medical Center of the National Hospital Organization.

Clinical trials are ongoing at Okayama City General Medical Center, Okayama City Hospital.

oncology

Treatment application for breast cancer patients currently under development with DAIICHI SANKYO COMPANY, LIMITED.

Chronic heart failure

The app is under development with our partners at YUMINO Medical Corporation.

In addition to the above, we offer mobile health programs for private companies through our Ascure Smoking Cessation Program and Targeted Health Guidance ascure Smoking Cessation Program, which leverage the knowledge we have gained through the development of these digital therapies for health care organizations. These programs have already been implemented in more than 230 companies and health insurers. In the future, we intend to introduce this “Japan-developed digital health solution” to the world one by one according to the model established in Japan.

CureApp, Inc. company profile

Deputy

director and

President

Kohta Satake

head office address

Kodenma-Cho YS Building 4th Floor 12-5, Nihonbashi Kodenma-Cho, Chuo-ku, Tokyo, Japan, 103-0001

US Branch

CureApp North America, Inc.

Business activities

Software Development as a Medical Device (SaMD), mobile services related to health

urls

https://cureapp.co.jp/en/

The source language in which the original text is published is the official and authorized version. Translations will be included for better understanding. Only the version in the language that was originally published is legally valid. Therefore, compare the translations with the original language version of the publication.

contacts:

[Anfragen]

Public Relations Representative, CureApp, Inc.

[email protected] (Mishima)

.

Leave your vote

Leave a Comment

Log In

Forgot password?

Forgot password?

Enter your account data and we will send you a link to reset your password.

Your password reset link appears to be invalid or expired.

Log in

Privacy Policy

Add to Collection

No Collections

Here you'll find all collections you've created before.